Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Blood (2023) 142 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2023-182347

Published: 2023

Journal Articles

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Maura Nicolosi, Valentina Bozzoli, Sabino Ciavarella, Cattina Federica, Gloria Margiotta Casaluci, Ombretta Annibali, Alessia Castellino, Francesco Rotondo, Luigi Petrucci, Federica Cocito, Sofya Kovalchuk, Erika Meli, Natalia Cenfra, Sara Bigliardi, Angelo Fama, Stefano Volpetti, Barbara Botto, Benedetto Bruno, Francesco Zaja

Blood (2023) 142 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2023-187563

Published: 2023

Journal Articles

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Alessia Ripamonti, Andrea Aroldi, Federica Cocito, Luca Guerra, Lavinia Monaco, Bianca Maria Granelli, Lara Mussolin, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2023-186702

Published: 2023

Journal Articles

Targeting CD24 “Don't Eat Me” Signal Restores Phagocytic Activity of Nurse-like Cells from Patients with Chronic Lymphocytic Leukemia

Andrea Aroldi, Mario Mauri, Daniele Ramazzotti, Simone Piane, Matteo Villa, Federica Malighetti, Chiara Borella, Elisa Bossi, Federica Cocito, Carolina Steidl, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2023-190359

Published: 2023

Journal Articles

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2023-173085

Published: 2023

Journal Articles

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

Andrea Aroldi, Mario Mauri, Matteo Villa, Federica Malighetti, Federica Cocito, Claudia Voena, Roberto Chiarle, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2022) 140 (Supplement 1): 3136–3138.

https://doi.org/10.1182/blood-2022-159247

Published: 2022

Journal Articles

CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma

Andrea Aroldi, Mario Mauri, Matteo Parma, Elisabetta Terruzzi, Marilena Fedele, Paola Perfetti, Federica Cocito, Luca Mologni, Roberto Chiarle, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2021) 138 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2021-154086

Published: 2021

Journal Articles

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Michele Merli, MD, Stefano Luminari, MD, Lucia Farina, Federica Cocito, MD, Irene Defrancesco, MD, Guido Gini, MD, Annalisa Arcari, MD, Greta Scapinello, MD, Massimo Gentile, MD, Maria Goldaniga, MD, Giacomo Loseto, MD, Emanuele Cencini, MD, Antonino Greco, MD, Andrea Ferrario, MD, Benedetta Bianchi, MD, Francesca Gaia Rossi, MD, Silvia Bolis, MD, Francesco Passamonti, MD, Luca Arcaini, MD

Blood (2018) 132 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2018-99-113536

Published: 2018

Journal Articles

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Federica Cocito, MD, Silvia Mangiacavalli, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5711.

https://doi.org/10.1182/blood.V128.22.5711.5711

Published: 2016

Journal Articles

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Silvia Mangiacavalli, MD, Federica Cocito, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, MD, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5695.

https://doi.org/10.1182/blood.V128.22.5695.5695

Published: 2016

Journal Articles

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

Federica Cocito, MD, Silvia Mangiacavalli, MD, Gabriella Ricciardelli, MD, Virginia Ferretti, PhD, Roberto Ceccuzzi, MD, Mario Cazzola, MD, paolo Emilio Bianchi, MD, Alessandro Corso

Blood (2014) 124 (21): 5691.

https://doi.org/10.1182/blood.V124.21.5691.5691

Published: 2014

Journal Articles

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Silvia Mangiacavalli, MD, Alessandra Pompa, MD, Cristiana Pascutto, PhD, Virginia Ferretti, DR, Lara Pochintesta, MD, Federica Cocito, MD, Marzia Varettoni, Mario Lazzarino, Prof, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2013) 122 (21): 1896.

https://doi.org/10.1182/blood.V122.21.1896.1896

Published: 2013

Journal Articles

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

Blood (2013) 122 (21): 687.

https://doi.org/10.1182/blood.V122.21.687.687

Published: 2013

Journal Articles

Bone Marrow Aspirate Can Be Avoided in Low-Risk MGUS Patients

Silvia Mangiacavalli, Federica Cocito, MD, Lara Pochintesta, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 3997.

https://doi.org/10.1182/blood.V120.21.3997.3997

Published: 2012

Journal Articles

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Lara Pochintesta, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 4003.

https://doi.org/10.1182/blood.V120.21.4003.4003

Published: 2012

Journal Articles

Fotemustine (MUFORAN) in Combination with Once Weekly Bortezomib and Dexamethasone (B-MuD): Good Clinical Activity and Favourable Toxicity Profile for Treatment of Relapsed Multiple Myeloma Patients.

Silvia Mangiacavalli, Alessandra Pompa, Lara Pochintesta, Cristiana Pascutto, Federica Cocito, MD, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 2957.

https://doi.org/10.1182/blood.V120.21.2957.2957

Published: 2012

Journal Articles

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Cesare Astori, MD, Marzia Varettoni, MD, Ester Orlandi, MD, Patrizia Zappasodi, MD, Silvia Rizzi, MD, Ilaria Ambaglio, MD, Mario Lazzarino, Prof, Mario Cazzola, MD

Blood (2010) 116 (21): 3037.

https://doi.org/10.1182/blood.V116.21.3037.3037

Published: 2010

Journal Articles

Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.

Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Annalisa Citro, Paola Brasca, Luigi Montalbetti, Patrizia Zappasodi, Federica Cocito, Marzia Varettoni, MD, Mario Lazzarino, MD, Enrica Morra, MD

Blood (2009) 114 (22): 1223.

https://doi.org/10.1182/blood.V114.22.1223.1223

Published: 2009

Journal Articles

Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases

Marzia Varettoni, MD, Gian Matteo Pica, MD, Federica Cocito, Silvia Mangiacavalli, Cristiana Pascutto, Mario Lazzarino, MD, Alessandro Corso, MD

Blood (2008) 112 (11): 2706.

https://doi.org/10.1182/blood.V112.11.2706.2706

Published: 2008

NARROW

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Targeting CD24 “Don't Eat Me” Signal Restores Phagocytic Activity of Nurse-like Cells from Patients with Chronic Lymphocytic Leukemia

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

Bone Marrow Aspirate Can Be Avoided in Low-Risk MGUS Patients

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Fotemustine (MUFORAN) in Combination with Once Weekly Bortezomib and Dexamethasone (B-MuD): Good Clinical Activity and Favourable Toxicity Profile for Treatment of Relapsed Multiple Myeloma Patients.

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.

Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only